Skip to main content
Orchid Pharma Limited logo

Orchid Pharma Limited — Investor Relations & Filings

Ticker · ORCHPHARMA ISIN · INE191A01027 LEI · 33580076KIKCYSLZVF05 BSE.NS Manufacturing
Open in API
Filings indexed 449 across all filing types
Latest filing 2024-02-08 Regulatory Filings
Country IN India
Listing BSE.NS ORCHPHARMA

About Orchid Pharma Limited

https://www.orchidpharma.com/

Orchid Pharma Limited is a vertically integrated organization focused on the development, manufacture, and marketing of Active Pharmaceutical Ingredients (APIs) and Finished Dosage Forms (FDFs). The company specializes in the anti-infectives segment, with a particular emphasis on cephalosporins and penicillins. Its operations span the entire value chain, including advanced research and development, process chemistry, and large-scale manufacturing. Orchid Pharma maintains facilities that adhere to rigorous international regulatory standards, enabling the supply of high-quality generic formulations and complex molecules to global markets. The company prioritizes innovation in chemical synthesis and formulation development to address complex therapeutic requirements and enhance healthcare outcomes through a robust portfolio of essential medicines.

Recent filings

Filing Released Lang Actions
Outcome of Board Meeting
Regulatory Filings
2024-02-08 English
Outcome of Board Meeting
Regulatory Filings
2024-02-08 English
Analysts/Institutional Investor Meet/Con. Call Updates
Regulatory Filings Classification · 95% confidence The document is an intimation about the schedule of an analyst/investor earnings call for Orchid Pharma Limited, specifically for the quarter ended December 31, 2023. It includes details about the date, time, participants, and dial-in numbers for the call. There is no actual financial data or results presented in the document, only an announcement of the upcoming earnings call event. According to the classification rules, such a document is best classified as a Call Transcript (CT) category if it contained the full transcript, but since this is only a schedule/intimation of the call, it is more appropriate to classify it as a Regulatory Filing (RNS) because it is a general regulatory announcement about the earnings call schedule without substantive financial content or transcript. The document length is short (3434 characters), and it does not contain the actual earnings release or transcript, so it is not an Earnings Release (ER) or Call Transcript (CT). Therefore, the best fit is Regulatory Filings (RNS).
2024-02-05 English
Board Meeting — ORCHID PHARMA LIMITED has informed the Exchange about Board Meeting to be held on 08-Feb-2024 to inter-alia consider and approve the Unaudited Financial results of the Company for the…
Regulatory Filings
2024-02-02 English
Board Meeting — Financial Results
Board/Management Information Classification · 95% confidence The document is a formal notice from Orchid Pharma Limited to stock exchanges about an upcoming Board Meeting scheduled for February 08, 2024. The purpose of the meeting is to consider and approve the Un-Audited Standalone & Consolidated Financial Results for the quarter ended December 31, 2023. The document references Regulation 29 of SEBI (Listing Obligations and Disclosure Requirements), which pertains to disclosures about board meetings. The document does not contain the financial results themselves, nor detailed financial data or analysis. It is an announcement of a board meeting where financial results will be approved, not the results or report itself. The document length is short (2449 characters), and it serves as an intimation or notice. Therefore, it fits best under Board/Management Information (MANG), which includes announcements of board meetings and related disclosures.
2024-02-02 English
Updates
Regulatory Filings Classification · 95% confidence The document is a disclosure made under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. It informs about the deregistration of a wholly owned subsidiary, Orchid Pharmaceuticals SA, and provides details as required under the regulation. The content is an official announcement regarding a corporate event (subsidiary deregistration) rather than a financial report or detailed management discussion. The document length is 4503 characters, which is relatively short and consistent with a regulatory announcement. There is no financial data, earnings information, or detailed report content. Therefore, this fits best under Regulatory Filings (RNS), which is the fallback category for regulatory announcements that do not fit other specific categories.
2024-02-01 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.